Research Analysts Set Expectations for NKTR Q3 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Investment analysts at Zacks Research increased their Q3 2026 earnings estimates for shares of Nektar Therapeutics in a note issued to investors on Thursday, September 3rd. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of ($2.45) for the quarter, up from their previous forecast of ($3.05). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($8.28) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q4 2026 earnings at ($3.07) EPS, FY2026 earnings at ($8.58) EPS, Q1 2027 earnings at ($3.17) EPS, Q2 2027 earnings at ($3.06) EPS, Q3 2027 earnings at ($4.28) EPS, Q4 2027 earnings at ($5.65) EPS, FY2027 earnings at ($16.15) EPS, Q1 2028 earnings at ($4.28) EPS, Q2 2028 earnings at ($3.82) EPS and FY2028 earnings at ($17.77) EPS.

A number of other brokerages also recently issued reports on NKTR. Canaccord Genuity Group assumed coverage on shares of Nektar Therapeutics in a report on Wednesday, July 22nd. They issued a “buy” rating and a $153.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a research report on Friday, August 28th. Wedbush cut their target price on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, May 11th. TD Cowen raised shares of Nektar Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Nektar Therapeutics in a report on Friday, August 21st. They issued a “neutral” rating and a $65.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $141.50.

Nektar Therapeutics Price Performance

Shares of Nektar Therapeutics stock opened at $74.19 on Monday. Nektar Therapeutics has a 52 week low of $33.40 and a 52 week high of $109.00. The stock’s 50-day simple moving average is $71.98 and its 200-day simple moving average is $72.10. The company has a market capitalization of $2.53 billion, a price-to-earnings ratio of -11.07 and a beta of 1.14.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.74. The company had revenue of $10.13 million during the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%.

Insider Buying and Selling at Nektar Therapeutics

In related news, CEO Howard Robin sold 418 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the completion of the sale, the chief executive officer directly owned 54,627 shares in the company, valued at $3,932,051.46. This trade represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jonathan Zalevsky sold 5,681 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $70.00, for a total transaction of $397,670.00. Following the completion of the sale, the insider owned 9,756 shares of the company’s stock, valued at $682,920. This trade represents a 36.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,823 shares of company stock worth $1,380,558 in the last 90 days. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Nektar Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 210 shares in the last quarter. KBC Group NV purchased a new position in shares of Nektar Therapeutics during the first quarter worth approximately $52,000. Headlands Technologies LLC purchased a new position in shares of Nektar Therapeutics during the second quarter worth approximately $65,000. State of Wyoming bought a new stake in shares of Nektar Therapeutics during the first quarter valued at approximately $67,000. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Nektar Therapeutics during the first quarter valued at approximately $68,000. 75.88% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.